High Potent API Development Services

We are committed to provide our clients with the safe, scalable and phase appropriate solutions for high potent drug development.

We offer highly potent small molecule development services for API and intermediates, operating from our development facility in Hyderabad, India. The development lab can handle molecules with OEL 0.1 µg/m³. We have a systematic approach to managing High potent APIs. which makes us one of the safest partners of choice for all your discovery needs.

We can handle various potent molecules viz., heterocyclic, nucleosides, steroids and carbohydrates.

Our approach for HPAPI handling

Speak to our experts

Dedicated HPAPI Labs

Self-equipped high potent chemical development lab with fume hoods (with negative pressure), barrier isolation, balance connected with isolator
Multi-purpose solids handling suites
High potent analytical labs with dedicated equipment connected with pass box
Biometric access control system
Capable to take up the development of HPAPI/Intermediates with OEL of 0.1µg/m³
Man-material entry and exit are separated to avoid contamination
Mist shower facility available for exit

Dedicated High Potent Analytical Lab

HPLC instrument with UV, DAD and CAD detectors
Gas chromatography with ALS and headspace injectors
Analytical balance (placed in Xpert filtered balance system)
pH meter
Ultrasound sonicator and rotary shaker
Zeta sizer
Isolator with HEPA cartridge for closed handling of the HPAI compounds
Pass box for sample transfer and atmos bag
Fume hood chemical handling and mobile phase preparations

Why Aurigene High Potent API Development Services?

Integrated development and manufacturing

Dedicated analytical lab

Well-experienced team

Legacy of having developed and manufactured complex high potent products

Other Services

Carbohydrate Development and Manufacturing Services

Peptide Development and Manufacturing Services

Steroid Development and Manufacturing Services

Virtual Tour

Hyderabad R and D Center

Bangalore R and D Center

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

I agree to receive updates from Aurigene

* I agree and accept the Privacy Policy and Terms of Use of this website.

Page name

page url

Learning Resources

Application and Manufacturing of High Potent Active Pharmaceutical Ingredient (HPAPI)

High Potent Active Pharmaceutical Ingredient (HPAPIs) are majorly used to treat oncology-related conditions. Usually, a compound is considered high-potent when the operational exposure limit is below 10 µg/m3 of air as an 8-hour time-weighted average. High Potent drugs can be administrated through oral, injection or topical route depending on the source of the d...

View All

HPAPI Development at a Glance

The pharmaceutical industry's journey to improve patients' health has enhanced the number of more effective HPAPIs (High Potent Active Pharmaceutical Ingredient) in development pipelines. Traditionally, HPAPIs were exclusively concomitant with oncology therapeutics. ...

View All

High Potent API (HPAPI) Manufacturing Services

Aurigene Pharmaceutical Services has experience, expertise and infrastructure to develop and manufacture oncology drug candidates including HPAPI ...

View All

Delivering 3 g dose of emetic and poorly bioavailable compound for 90 days repeated dose toxicity studies in dog

Background: Develop oral liquid dosage form of an IND candidate (small molecule) suitable for chronic toxicology studies in dogs. Must meet required systemic exposure and shall be dose proportional. Developed vehicle or used excipients shall be safe for chronic preclinical toxicology studies in dog. Challenges: Conventional suspension in dog resulted in low oral ...

View All

Construction of a quinoline ring via a 3-component reaction in water: crystal structure analysis and H-bonding patterns of a 2-aryl quinoline

2012

Montmorillonite K-10 mediated green and one-pot synthesis of 2-substituted quinolines has been accomplished via a 3-component reaction of aniline, aldehydes and ethyl 3,3- diethoxypropionate in the presence of air oxygen in water. The crystal structure analysis and H-bonding patterns of one compound prepared are presented. ...

Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques

Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More
Development of novel paullone-based PROTACs as anticancer agents

Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation

Decitabine is an anti-cancer chemotherapy drug. This article describes method development and method verification of Assay of Decitabine in tablet formulation. A new, precise, rapid, accurate RP-HPLC method has been developed for the estimation of Decitabine in pharmaceutical tablets dosage form. After optimization the good chromatographic separation was achieved...
Read More

View All

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

Proceed Back